Chronic Fatigue
Peptides discussed for chronic fatigue and mitochondrial dysfunction — MOTS-c, SS-31 / elamipretide, humanin, thymosin-α1, and BPC-157. Mechanism and evidence.
Chronic fatigue is a symptom that runs through dozens of underlying conditions — myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS), post-COVID syndrome ('long COVID'), fibromyalgia, hypothyroidism, anemia, sleep apnea, depression, autoimmune disease, and aging-related decline among them. Mitochondrial dysfunction has been implicated as a shared downstream feature of many chronic fatigue presentations: reduced oxidative phosphorylation efficiency, increased oxidative stress, altered substrate utilization, and impaired mitochondrial biogenesis show up across multiple chronic fatigue contexts.
The peptide conversation around chronic fatigue clusters around mitochondrial-targeted compounds. Mitochondrial-derived peptides — MOTS-c, humanin, SHLPs — have emerged as a class of small peptides encoded within mitochondrial DNA that act as metabolic regulators with effects on insulin sensitivity, mitochondrial biogenesis, and stress resilience. SS-31 (the active component of elamipretide) is a Szeto-Schiller cationic tetrapeptide that targets the inner mitochondrial membrane and stabilizes cardiolipin, improving electron transport chain efficiency. Beyond the mitochondrial peptides, thymosin-α1 (for immune-driven fatigue) and BPC-157 (for the GI and inflammation contributions to fatigue) round out the conversation.
This page covers what these peptides do, the gap between mitochondrial mechanism and clinical fatigue evidence, and how to think about peptides relative to the standard chronic fatigue workup. The framing matters: chronic fatigue with measurable cause (anemia, hypothyroidism, sleep apnea) is treated by addressing the cause. Chronic fatigue without identifiable cause — genuine ME/CFS or long COVID fatigue — is harder, has fewer validated treatments, and is the population for whom mitochondrial peptides have the most theoretical relevance.
Peptides discussed for Chronic Fatigue
Elamipretide
Mitochondrial Peptide
The first FDA-approved mitochondria-targeted peptide. Stealth BioTherapeutics received accelerated approval in September 19, 2025 for Barth syndrome — a rare X-linked cardiolipin disorder affecting roughly 150 people in the US — marketed as Forzinity.
Thymosin Alpha-1
Thymic Peptide
A thymic peptide approved in multiple countries for immune modulation, particularly in hepatitis and as a vaccine adjuvant.
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
SS-31
Mitochondrial Peptide
A mitochondria-targeted cardiolipin-stabilizing tetrapeptide FDA-approved in September 2025 as Forzinity for Barth syndrome — the first approved mitochondria-targeted peptide — with ongoing trials in dry AMD, mitochondrial myopathy, and heart failure.
Humanin
Mitochondrial-Derived Peptide
A mitochondria-derived peptide with cytoprotective properties, studied for neuroprotection, metabolic regulation, and anti-aging effects.
MOTS-c
Mitochondrial Peptide
A mitochondria-derived peptide that regulates metabolic homeostasis and has been called an 'exercise mimetic.'
How peptides target chronic fatigue
Five peptides come up in chronic fatigue discussions. First, MOTS-c (mitochondrial open reading frame of the twelve S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA and discovered around 2015. It acts as a metabolic regulator — improving insulin sensitivity, activating AMPK, increasing mitochondrial biogenesis through effects on PGC-1α, and supporting metabolic flexibility. Animal and early-human studies show effects on exercise capacity, glucose tolerance, and aging-related metabolic decline. The fatigue rationale is that improved mitochondrial function should translate to improved energy availability.
Second, SS-31 (elamipretide, the cationic Szeto-Schiller tetrapeptide D-Arg-Tyr(Me)-Lys-Phe-NH₂) targets cardiolipin in the inner mitochondrial membrane and stabilizes electron transport chain organization. It has been studied in clinical trials for primary mitochondrial myopathies (MMPOWER program), Barth syndrome, and heart failure with preserved ejection fraction. Outside mitochondrial diseases, SS-31 has been investigated for age-related skeletal muscle dysfunction and fatigue in older adults.
Third, humanin is another mitochondrial-derived peptide (24 amino acids) with neuroprotective and metabolic regulatory effects, also studied in aging contexts.
Fourth, thymosin-α1 (Zadaxin) modulates innate immunity and has been studied in chronic immune dysfunction including post-viral fatigue states.
Fifth, BPC-157 enters this conversation more peripherally — through the gut-fatigue connection (GI inflammation contributing to systemic fatigue) and through its general protective and anti-inflammatory effects.
What the evidence shows
SS-31 / elamipretide has the most clinical trial development. The MMPOWER program ran multiple Phase II/III trials in primary mitochondrial myopathies — results were mixed, with some endpoint successes and some failures, ultimately producing FDA approval for Barth syndrome (Forzinity, 2025) but not approval for the broader primary mitochondrial myopathy indication. The clinical pathway demonstrates that the molecule has real biological effects in mitochondrial disease but has been challenging to translate into approval for fatigue-prominent indications.
MOTS-c has growing animal and early-human evidence for metabolic and exercise-capacity effects but limited published human trial data specifically for chronic fatigue or ME/CFS. The biology is interesting and the mitochondrial-derived peptide field is expanding rapidly, but clinical translation for fatigue indications is in early stages.
Thymosin-α1 has a substantial real-world clinical use base in over 30 countries but is not specifically validated for chronic fatigue syndrome.
BPC-157 has no specific chronic fatigue trial evidence — its relevance is indirect through GI and inflammation pathways.
For ME/CFS specifically, there are no FDA-approved treatments, and the validated supportive interventions (pacing, graded activity carefully managed to avoid post-exertional malaise, addressing concurrent depression and sleep dysfunction, low-dose naltrexone in some cases) remain the foundation. Peptides for ME/CFS are speculative at this stage — mechanistically plausible, clinically unvalidated.
What to expect
Reported regimens vary widely. MOTS-c at 5-10 mg subcutaneous injection 2-3 times weekly for 4-8 week courses is the most common protocol described. SS-31 / elamipretide in clinical contexts is administered subcutaneously daily; off-label use mimics this regimen. Thymosin-α1 at 1.6 mg twice weekly is a typical clinician-directed dose.
Magnitude of expected effect: variable. Some users report meaningful improvement in energy, exercise tolerance, and post-exertional recovery; others report nothing. The heterogeneity of chronic fatigue presentations — different underlying biology in different patients — likely contributes to inconsistent peptide response.
The critical context: workup matters. Chronic fatigue has dozens of treatable causes that should be ruled out before assuming a primary mitochondrial or peptide-responsive etiology. Comprehensive workup includes CBC, ferritin, TSH/free T4, vitamin D, B12, comprehensive metabolic panel, sleep evaluation if indicated, depression screening, autoimmune screening if other features suggest it, and ECG if exertional symptoms are prominent. A clean workup followed by ME/CFS-pattern symptoms (post-exertional malaise, unrefreshing sleep, cognitive impairment) is the population for whom mitochondrial peptides become more reasonable to consider.
Important caveats
Persistent fatigue with red flags — significant unintended weight loss, fevers, night sweats, swollen lymph nodes, exertional chest pain, severe depression with suicidal ideation — needs medical evaluation, not peptides. Cardiac, infectious, autoimmune, and malignant causes can present with fatigue and require disease-specific treatment. Sleep apnea is dramatically underdiagnosed in fatigue and should be evaluated when there are any suggestive features. Pregnancy, breastfeeding, and active malignancy are situations where peptide protocols should be deferred. People with diagnosed ME/CFS or long COVID who are pacing carefully should be cautious about any intervention that might encourage premature increase in activity, since post-exertional malaise can produce significant prolonged setback.
Frequently asked questions
What is the best peptide for chronic fatigue?
Depends on the underlying biology. For diagnosed primary mitochondrial myopathy, elamipretide (SS-31) has FDA approval for Barth syndrome and Phase III development in other mitochondrial diseases. For metabolic dysfunction-driven fatigue, MOTS-c is the most-discussed off-label option. For post-viral or immune-dysfunction fatigue, thymosin-α1 has the most regulatory validation. For most ME/CFS, no peptide is validated — the underlying biology is heterogeneous and the controlled trial evidence does not yet exist.
Does MOTS-c work for chronic fatigue syndrome?
Mechanistically plausible — improved mitochondrial function and metabolic flexibility could plausibly help fatigue conditions where mitochondrial dysfunction is contributing. Evidence-wise, there are no published randomized controlled trials of MOTS-c for ME/CFS or long COVID fatigue. Animal and early-human data show metabolic and exercise-capacity effects in healthy and aging populations. Anecdotal reports of benefit in chronic fatigue exist but are not validated. People who try MOTS-c for chronic fatigue are extrapolating from preclinical data.
Are mitochondrial peptides safe?
The animal safety profiles of MOTS-c, humanin, and SS-31 are favorable. Elamipretide / SS-31 has the most clinical safety data — multiple Phase II/III trials in mitochondrial myopathy and heart failure produced no characteristic serious organ toxicity. The major safety unknown for off-label MOTS-c use is product quality from research-chemical suppliers. People with active malignancy should avoid these peptides until oncologist-cleared because of theoretical effects on metabolic pathways tumors hijack.
Can peptides treat long COVID fatigue?
Anecdotally, yes — many long COVID protocols include peptides among interventions tried, particularly BPC-157, thymosin-α1, MOTS-c, and SS-31. Controlled trial evidence in long COVID specifically is limited or in early stages. The biology of long COVID fatigue (mitochondrial dysfunction, persistent inflammation, microvascular changes, possible viral persistence) makes peptide protocols mechanistically reasonable. Validated long COVID treatment is still emerging, and peptides should be considered alongside (not instead of) the multidisciplinary care that long COVID often requires.
How long until peptides work for chronic fatigue?
Reported timelines vary widely. Subjective effects from MOTS-c sometimes appear in 1-2 weeks; cumulative changes over 4-8 week courses. SS-31 in clinical contexts is dosed daily for months. Thymosin-α1 is typically dosed weekly for months. None of these is rapid; chronic fatigue interventions generally take weeks to months to assess and rebound after stopping is common when underlying causes are not addressed.
Should I get checked out before trying peptides for fatigue?
Yes. Chronic fatigue has dozens of treatable causes — anemia, hypothyroidism, sleep apnea, depression, vitamin D and B12 deficiency, untreated infection, autoimmune disease — that should be ruled out before assuming a primary mitochondrial or peptide-responsive cause. Basic workup (CBC, ferritin, TSH, vitamin D, B12, comprehensive metabolic panel, sleep history, depression screening) catches the bulk of these. Peptide protocols make sense after this workup is clean, not as a substitute for it.
Part of these goals
Related conditions
Peptide families relevant to Chronic Fatigue
Updated 2026-05-07